Alameda Mobile App Cross Platform Development
BASIC
- Around 5 Screens.
- Around 5 Integrations
- Only simple validations on device
- No-obligation inquiry.
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
STANDARD
- Around 10 Screens
- Around 10 Integrations
- Simple business logic for Validations / Calculations / Chart Data etc.
- Some local storage of data
- Team consists of: Dev Team - 1 Developer (full time) QA Team - 1 Test Engineer (shared)
- 1 Project Manager (shared)
- 1 Team Lead (shared)
PREMIUM
- Around 20 Screens
- Around 20 Integrations
- Complex business logic like Interactive Charts, Animations, Validations, Conditions etc.
- Complete local storage of data used by App
- We will create suggestions on monthly basis for improvement for you.
Cross-Platform App Development Services & Solutions in Alameda
We take your groundwork and create a market-ready app based on your needs while you focus on product and company growth.
Flutter is the fastest-growing cross-platform development framework. It was introduced in 2017 by Google and managed to gain great popularity among cross-platform programmers.
Alameda News
Science Corp. wants to develop miniaturized, portable ECMOs
Science Corp. — better known for its brain-computer interface work — is in the early stages of reimagining extracorporeal membrane oxygenation.
A Brain-Computer Interface Company Is Getting Into Organ Preservation
Science Corporation, founded by Neuralink’s first president, Max Hodak, has unveiled a prototype machine to extend the life of organs for longer periods.
Forbes Daily: A New Era For Cannabis As Trump Reclassifies Marijuana
Today’s Forbes Daily also covers TikTok's agreement with American investors, slower inflation, Trump Media's nuclear fusion deal, a private defense billionaire and more.
Out of a superhero movie: Companies are coming up with plans to block out the sun
Private companies are jumping into the race to deploy particles to the atmosphere to reduce global warming, prompting enthusiasm from investors and concerns from some scientists, Josh Marcus reports ...